Drug Information Association Logo

DIA 2014 9th Annual India Conference: The Future of Indian Health Care: Patients, Access and Innovation

Oct 16 2014 7:00AM - Oct 18 2014 6:00PM | Palladium Hotel, Mumbai 462, Senapati Bapat Marg, Lower Parel, Mumbai 400013 India

« Back to Listing


Good health is a fundamental human right. But despite rapid improvements in the recent past, there are unprecedented healthcare challenges in India today that demand immediate attention and action. The most critical aspect among these is ensuring safety, efficacy, quality, affordability and accessibility of medicines and treatment to patients at all times. The key imperatives to overcome these continual challenges and catalyze the transformation include putting patients first, fostering innovation, and enhancing access. The DIA 2014 9th Annual India Conference will bring together leading local and global experts in health care, pharmaceutical industry members, academia, researchers, regulators, payers and patients under one roof to deliberate on the emerging trends, opportunities and challenges.

Featured Topics 

Program Objectives:
  • Focusing on ‘Patient First’ approach and various patient centric paradigms covering innovation and access of Indian healthcare
  • Hear the views of leading experts from the academia, government, industry, researchers, patient representatives and regulators on current local and global trends and best practices
  • Bringing all healthcare stakeholders together to discuss current issues/topics
  • Covering important issues/topics such as, patient health and safety, pharmacovigilance, clinical trial, quality and manufacturing, health economics, healthcare delivery, public-private partnership in innovation and healthcare access, case studies on Indian innovation and many more

Who Should Attend 

  • Drug development and clinical research managers and associates
  • Pharmaceutical physicians and medical directors
  • Drug safety and drug surveillance personnel
  • Professionals engaged in discovery research
  • Clinical pharmacology scientists
  • Pharmacologists
  • Regulatory affairs managers
  • Quality professionals
  • Academic scientists
  • Biostatisticians
  • Data managers
  • Medical writers
  • Outsourcing and marketing managers
  • IT professionals
  • Patient Engagement Stakeholders

Contact Information 

Manoj Trivedi, Senior Manager Marketing and Program Development, DIA India
Mobile phone: +91-98-1977-7493
Phone: +91-22-6765-3226
Email: Manoj.Trivedi@diaindia.org

Rajnish Kumar
DIA India/CIMGlobal Sales Lead
Mobile phone: +91.98.1909.8457
Email: rajnish.kumar@diaindia.org


Featured Speaker 

Previous Next

Program Committee 

Previous Next


Day 1 Thursday, Oct 16, 2014

  • 10:30AM - 11:00AM (India Standard Time)

    Day 1 Keynote


    • M K Bhan
      Former Secretary, Department of Biotechnology (DBT)
      Government of India, India
  • 11:00AM - 12:00PM (India Standard Time)

    Plenary Session 1: Patients

    Session Chair(s):

    • No-image Vikas Sharma
      Senior Director, Medical Ethics & Research Office of CMO and Scientific Officer
      Quintiles, India

    The opening session sets forth the tone and content of the prevailing thinking and practice in the clinical research and patient care space which is undergoing a paradigm shift. The patients’ voice and perspective is coming to the fore as a definite patient centric approach. The topics will help provide holistic insight to the current issues and orient future thinking.


    • Hari Menon
      Professor, Dept. of Medical Oncology
      Tata Memorial Centre, India
    • Urmila Thatte
      Professor and Head, Seth GS Medical College
      KEM Hospital, India
    • Satish Chandra
      Senior Specialist and Head Clinical Research
      TAWAM Hospital (associate of John Hopkins), United Arab Emirates
    • Y K Gupta
      Professor and Head, Department of Pharmacology
      All India Institute of Medical Sciences (AIIMS), India
    • Pooja Sharma
      Leader (Hon) CANKIDS Patient Advocacy Group;
      Senior Scientist, Clinical Research, Medanta the Medicity, India
  • 1:30PM - 3:00PM (India Standard Time)

    Session 1A: Patient Health Safety and Compliance for Prescription Medicine

    Session Chair(s):

    • No-image Padmashri Prof. Ranjit Roy Chaudhury
      Chairman, Task Force for Research
      Apollo Hospitals Group, India

    This session will address issues surrounding the use of medicines by patients in India, including compliance with prescribed medicines and how to ensure the safe use of medicines.


    • Regulatory Initiatives to Enhance Compliance
      V G Somani
      Joint Drug Controller
      CDSCO, India
    • Preventing Errors in Using Medicines
      Pramil Tiwari
      Head and Professor, Department of Pharmacy Practice
      NIPER, India
    • Increasing Compliance in Patients
      Prem Pais
      Professor of Medicine, Head of Division of Clinical Research Training
      St. John's Institute , India
  • 1:30PM - 3:00PM (India Standard Time)

    Session 1B: Pharmacovigilance in India

    Session Chair(s):

    • Ajoy Roy
      Senior Medical Director and Head Medical Affairs
      PAREXEL, India

    This session will describe the status of pharma- covigilance regulation and practices in India, with a focus on monitoring the safe use of markets drugs and ways to take prompt remedial action when and if necessary.


    • Postmarketing Pharmacovigilance Regulations and Practices in India
      Y K Gupta
      Professor and Head, Department of Pharmacology
      All India Institute of Medical Sciences (AIIMS), India
    • Clinical Trials Safety Regulations in India - Current Scenario and Global Perspective
      Vivek Ahuja
      Director, Research & Development
      PATH, India
    • A SWOT Analysis of Growing Pharmacovigilance Industry in India
      Mangesh Kulkarni
      Head Safety Operations, Drug Safety & Epidemiology
      Novartis Healthcare Pvt. Ltd., India
  • 3:30PM - 5:00PM (India Standard Time)

    Session 2A: Status of Patient Advocacy Groups in India

    Session Chair(s):

    • Mira Shiva
      Chairperson, Health Action International Asia-Pacific
      Founder, People's Health Movement, India

    This session will provide current information on the status and influence of patient advocacy groups in India, their goals and aspirations, their success and ongoing concerns, and the issues that remain to be addressed to protect patient safety and promote patient health.


    • Y K Sapru
      Cancer Patients Aid Association , India
    • Vikas Ahuja
      The Delhi Network of Positive People , India
    • Blessina Kumar
      Global Coalition of TB Activists, India
  • 3:30PM - 5:00PM (India Standard Time)

    Session 2B: Patient Participation in Clinical Trials

    Session Chair(s):

    • Barbara E. Bierer
      Professor of Medicine, Harvard Medical School; Co-Director MRCT
      Brigham and Women's Hospital Faculty Co-Director, United States

    This session will focus on the important ethical issues and practical logistics (for example, travel from rural areas) affecting the participation of patients in clinical trials in India, the stricter applicable regulations (for example, videotaped informed consents), the protection of the rights on trial participants and of the validity of the data, and the oversight of clinical investigators.


    • International Clinical Trials Data Sharing: Principles and Mandate
      Mark Barnes
      Partner, Ropes & Gray LLP; Lecturer on Law, Harvard Law School
      Faculty Co-Director MRCT, Harvard University, United States
    • Return of Summary Results to Participants: Regulation, Content and Process
      Barbara E. Bierer
      Professor of Medicine, Harvard Medical School; Co-Director MRCT
      Brigham and Women's Hospital Faculty Co-Director, United States
    • Participant Understanding and Informed Consent
      Kimberly Hensle Lowrance
      Managing Director
      Public Responsibility in Medicine and Research (PRIM&R), United States

Day 2 Friday, Oct 17, 2014

  • 10:30AM - 11:00AM (India Standard Time)

    Day 2 Keynote


    • G N Singh
      Drug Controller General of India (DCGI)
  • 11:00AM - 12:30PM (India Standard Time)

    Plenary Session 2: Access

    Session Chair(s):

    • No-image Nata Menabde
      Representative to India
      WHO, India

    The plenary session intends to generate directional thought leadership to arrive at a unique and integrated healthcare model.The session will help to analyse and suggest future model which leverages principle of accessibility, affordability and accountability by adopting a patient-centric approach towards delivery of quality healthcare to the masses. The session will also invite opinions from the panel members and participants to understand possible impact and adoption of Health Care Economic Outcomes Research (Pharmacoeconmics), Health Insurance, Public Private Partnerships, Diagnostics & Pharma Industry – covering the Healthcare Value Chain.


    • Swati Piramal
      Vice Chairman
      Piramal Enterprise Ltd., India
    • N K Ganguly
      Former Director General
      Indian Council of Medical Research (ICMR), India
    • Devi Shetty
      Narayana Hrudayalaya Group of Hospitals, India
    • Rajesh Balkrishnan
      Associate Professor Health Outcomes
      University of Michigan, United States
    • Ferzaan Engineer
      Co-Founder and Chairman
      Cytespace, India
  • 1:30PM - 3:00PM (India Standard Time)

    Session 3A: Universal Health Coverage and Health Insurance

    Session Chair(s):

    • Antonio Duran
      Technical Advisor
      WHO, India

    The goal of this session is to take stock of the current state and future prospects for universal health coverage and health insurance for patients in India, with particular reference to patient access to registered safe and effective medicines.


    • Access to Medicines and Health Technologies in the Context of Universal Healthcare Coverage in India: Opportunities and Challenges
      Madhur Gupta
      Technical Officer - Pharmaceuticals
      WHO, India
    • No-Return Progress Without Maximalist Attitudes: The India Way Towards Universal Health Coverage
      Antonio Duran
      Technical Advisor
      WHO, India
    • Universal Health Coverage: Concerns and Options
      Indrani Gupta
      Professor and Head, Health Policy Research Unit
      Institute of Economic Growth, India
  • 1:30PM - 3:00PM (India Standard Time)

    Session 3B: Medicine Pricing and Reimbursement

    Session Chair(s):

    • Manu Sehgal
      Vice President
      PAREXEL, India

    Speakers in this session will illustrate the various existing public and private mechanisms for the pricing and reimbursement of medicines in India, with a focus on how patients at all income levels can have access to the medicines they need, on what obstacles may exist to such access, and on possible ways to remove such obstacles.


    • Insight into India's Pharmaceutical Pricing Policy: Will the Revised Policy Improve Access to Medicines?
      Anita Kotwani
      Associate Professor, Department of Pharmacology
      Vallabhai Patel Chest Institute, University of Delhi, India
    • Medicine Reimbursement in India Present and Future
      Anuj Kapoor
      Senior Manager Operations, Health Economics & Outcome Research Practice
      Optum Global Solutions, India
  • 3:30PM - 5:00PM (India Standard Time)

    Session 4A: Good Manufacturing Practices - Panel Discussion

    Session Chair(s):

    • Ganadhish Kamat
      Executive Vice President, Quality
      Lupin, India

    Pharmaceutical GMP in modern times is not just an assessment through testing the finished product but is an ongoing discipline that one has to be imbibe from product development to product distributed the patients. GMP poses a significant challenges in terms of bridging – What Agency Wants and What Industry Understands. This GMP session covers the current GMP challenges of Indian Pharmaceutical/Healthcare industry and the path to be traversed moving forward.


    • Vikas Dandekar
      India Bureau Chief
      PharmAsia News , India
    • Ajaz Hussain
      President & CEO
      Insight Advice & Solutions, United States
    • Nick Cappuccino
      Chief Technical Officer & Scientific Advisor
      Dr. Reddy's Laboratories, United States
  • 3:30PM - 5:00PM (India Standard Time)

    Session 4B: Compulsory Licensing - Increasing Tool for Easy Access of Medicines - Panel Discussion

    Session Chair(s):

    • Aliasgar Dholkawala
      Senior Associate, Legal Services
      Wadia Ghandy & Co., India

    This session will examine and debate the important and delicate issue of compulsory licensing of medicines and both its intended (affordable access to medicines) and unintended (obstacle to theentry of innovation into India) consequences.


    • Milind Sathe
      Deputy General Manager, IPM & Projects
      Unichem, India
    • Alka Mehta
      Head Formulations
      Cipla, India
    • Tabrez Ahmad
      Secretary General
      Organization for Pharmaceutical Products of India (OPPI), India
    • Smita Karve
      Professor of Law
      Jitendra Chauhan College of Law, India

Day 3 Saturday, Oct 18, 2014

  • 9:30AM - 10:00AM (India Standard Time)

    Day 3 Keynote


    • Kiran Mazumdar Shaw
      Chairman and Managing Director
      BIOCON, India
  • 10:30AM - 11:30AM (India Standard Time)

    Plenary Session 3: Innovations

    Session Chair(s):

    • No-image Arun Mishra
      Director and Head, Regulatory Affairs
      Abbott India Ltd., India


    • V V S Swaroop
      Managing Director and CEO
      Incozen Therapeutics, India
    • Padmashri Prof. Ranjit Roy Chaudhury
      Chairman, Task Force for Research
      Apollo Hospitals Group, India
    • Mohan D. Nair
      Consultant to Pharmaceutical Industry, India
    • Romi Singh
      Executive Director
      Amgen, United States
    • Manoj Malhotra
      CEO, Pyramid Healthcare, Salient Business Solutions
      Avantha Group, India
  • 11:30AM - 1:00PM (India Standard Time)

    Session 5: Innovation in Drug Discovery and Development

    Session Chair(s):

    • Neelima Khairatkar Joshi
      Senior Vice President and Head NCE Drug Discovery & Research
      Glenmark, India

    Speakers in this session will illustrate the current status of pharmaceutical innovation in India – from scientific discovery to the development of innovative drugs that change the practice of medicine. Can Indian R&D improve its competitiveness on world markets?


    • Latest Trend in Cancer Therapy
      V V S Swaroop
      Managing Director and CEO
      Incozen Therapeutics, India
    • The need for New Innovative Approaches to New Drug Discovery
      Mohan D. Nair
      Consultant to Pharmaceutical Industry, India
    • Clinical Trials in 2020
      Rajesh Jain
      Director, Life Sciences Business Process Services
      Cognizant Technology Solutions India Pvt. Ltd., India
  • 2:00PM - 4:00PM (India Standard Time)

    Session 6: Innovations in Healthcare Solutions

    Session Chair(s):

    • Sudharshan Jain
      Managing Director, Healthcare Solutions
      Abbott India Ltd., India

    This session will address examples of how certain Indian healthcare solutions have been highly innovative and have delivered concrete benefits to millions of patients. Speakers will address what additional actions need to be taken to expand such innovation to the entire Indian patient population.


    • Affordable Healthcare Driving Reverse Innovation .... A New Normal in the Bipolar World
      Abhishek Bhattacharya
      Vice President, Life Sciences Operations
      Accenture Services Pvt. Ltd., India
    • Indigenous Innovation in Medical Technology: An Emerging Paradigm
      Siraj Dhanani
      Founder and CEO
      Innaccel Pvt. Ltd., India
    • Empowering Frontline Health Workers with Technology
      Kanav Kahol
      Division Head, Affordable Health Technologies Division
      Public Health Foundation of India, India
    • Big Data Analytics for Developing Nations: How Secondary use of EHR Data can help India
      Gunjan Jain
      Principle Sales Consulting Head, South Asia
      Oracle HSGBU, India


The DIA 2014 9th Annual India Conference offers interested companies that opportunity to exhibit with a booth. Additional advertising and support opportunities also available.

Useful Links:

  • Abbott India Limited
  • Aptar Pharma India Pvt. Ltd.
  • Cognizant
  • Glenmark Pharmaceuticals Limited
  • Lambda Therapeutic Research Private Limited
  • LORENZ Life Sciences India Pvt. Ltd.
  • Quintiles Technologies (India) Private Limited
  • Sanofi Synthelabo India Limited
  • Tata Consultancy Services
  • the Uppsala Monitoring Centre

Registration Fees 

Other Fees

Indian Government (Full Time)
Indian Academia


Indian Member Standard
International Academia Member ($300USD)
International Government Member ($300USD)
International Industry Member ($300USD)


Indian NonMember Standard
International Academia Non-Member ($475USD)
International Government Non-Member ($475USD)
International Industry Non-Member ($475USD)
Group Discounts

GROUP DISCOUNT: Register 10 Delegates from your company and receive the 11th FREE!.

Online transactions are subjected to validation of registration rate once the online transaction is completed. You may be assessed with a different registration fee should the validation process result in your status to be otherwise submitted.

Find out more about the many benefits of membership and how you can get involved.

A limited number of student registrations are available. A student is an undergraduate/graduate who can document enrollment in a Signature accredited, degree granting, academic program. Please send completed registration form, copy of student identification, and payment.


Cancellations must be in writing and received by October 2, 2014. Registrants who do not cancel in writing by that date and do not attend the event will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations.

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

Upon cancellation, the administrative fee that will be withheld is 75% of the registration fee.

All refunds will be issued in the currency of original payment

Register Online
« Back to Listing Back To Top